Search research articles
Contact Us
Filters
Showing results (21-30 of 40) with videos related to
Page
of 4
Sort By:
British Journal of Haematology
|
July 1, 1991
Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor
M L Schmidt, H E Smith, S Gamerman, et al.
The Pediatric Infectious Disease Journal
|
March 1, 1994
Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children
E G Chadwick, G Chang, M D Decker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 22, 2001
Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa
S Sheth, D Dimichele, M Lee, et al.
Blood
|
February 1, 1997
Nephrotic syndrome as a complication of immune tolerance in hemophilia B
B M Ewenstein, C Takemoto, I Warrier, et al.
Haematologica
|
February 24, 2001
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors
B M Ewenstein, W K Hoots, J M Lusher, et al.
The Journal of Biological Chemistry
|
November 14, 1997
The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera
B C Furie, J V Ratcliffe, J Tward, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 19, 2007
Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
M A H Kurth, D Dimichele, C Sexauer, et al.
Thrombosis and Haemostasis
|
April 2, 1999
Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
G C White, D DiMichele, K Mertens, et al.
Journal of Thrombosis and Haemostasis : JTH
|
October 7, 2009
Pharmacokinetics and safety of fibrinogen concentrate
M J Manco-Johnson, D Dimichele, G Castaman, et al.
Retina (Philadelphia, Pa.)
|
September 8, 1998
Factor V Leiden, activated protein C resistance, and retinal vein occlusion
A P Ciardella, L A Yannuzzi, K B Freund, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 40) with videos related to
Sort By:
Page
of 4
British Journal of Haematology
|
July 1, 1991
Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor
M L Schmidt, H E Smith, S Gamerman, et al.
The Pediatric Infectious Disease Journal
|
March 1, 1994
Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children
E G Chadwick, G Chang, M D Decker, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 22, 2001
Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa
S Sheth, D Dimichele, M Lee, et al.
Blood
|
February 1, 1997
Nephrotic syndrome as a complication of immune tolerance in hemophilia B
B M Ewenstein, C Takemoto, I Warrier, et al.
Haematologica
|
February 24, 2001
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors
B M Ewenstein, W K Hoots, J M Lusher, et al.
The Journal of Biological Chemistry
|
November 14, 1997
The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera
B C Furie, J V Ratcliffe, J Tward, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 19, 2007
Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
M A H Kurth, D Dimichele, C Sexauer, et al.
Thrombosis and Haemostasis
|
April 2, 1999
Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
G C White, D DiMichele, K Mertens, et al.
Journal of Thrombosis and Haemostasis : JTH
|
October 7, 2009
Pharmacokinetics and safety of fibrinogen concentrate
M J Manco-Johnson, D Dimichele, G Castaman, et al.
Retina (Philadelphia, Pa.)
|
September 8, 1998
Factor V Leiden, activated protein C resistance, and retinal vein occlusion
A P Ciardella, L A Yannuzzi, K B Freund, et al.
Page
of 4